<DOC>
	<DOC>NCT02482454</DOC>
	<brief_summary>The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.</brief_summary>
	<brief_title>Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma</brief_title>
	<detailed_description>The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cholangiocarcinoma.</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>Patients with histologically confirmed cholangiocarcinoma Primary lesions (cholangiocarcinoma) are not resected Serum bilirubin level of 2.0 mg/dl or less. Performance status of 0 or 1. Expected survival of 1 year or more. Informed consent from the patient. With extrahepatic metastases With other neoplastic disease that is measurable or being treated other than cholangiocarcinoma.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>radiofrequency ablation</keyword>
	<keyword>cytokine-induced killer cells</keyword>
	<keyword>cholangiocarcinoma</keyword>
</DOC>